Thyroid hormone influence on oxygen consumption rates, body mass, and lipid metabolism in mice with noninsulin dependent diabetes mellitus by Clark, Catherine Renee
California State University, San Bernardino 
CSUSB ScholarWorks 
Theses Digitization Project John M. Pfau Library 
1995 
Thyroid hormone influence on oxygen consumption rates, body 
mass, and lipid metabolism in mice with noninsulin dependent 
diabetes mellitus 
Catherine Renee Clark 
Follow this and additional works at: https://scholarworks.lib.csusb.edu/etd-project 
 Part of the Endocrinology, Diabetes, and Metabolism Commons 
Recommended Citation 
Clark, Catherine Renee, "Thyroid hormone influence on oxygen consumption rates, body mass, and lipid 
metabolism in mice with noninsulin dependent diabetes mellitus" (1995). Theses Digitization Project. 
1025. 
https://scholarworks.lib.csusb.edu/etd-project/1025 
This Thesis is brought to you for free and open access by the John M. Pfau Library at CSUSB ScholarWorks. It has 
been accepted for inclusion in Theses Digitization Project by an authorized administrator of CSUSB ScholarWorks. 
For more information, please contact scholarworks@csusb.edu. 
THYROID HORMONEINFLUENCEON OXYGEN CONSUMPTION RATES,
 
BODY MASS, AND LIPID METABOLISMIN MICE WITHNONINSULIN
 
DEPENDENTDIABETES MELLITUS
 
A Thesis
 
Presented to the
 
Faculty of
 
California State Umversity,
 
San Bernardino
 
In Partial Fulfillment
 
ofthe Requirements for the Degree
 
Master ofScience
 
in
 
Biology
 
by
 
Catherine Renee Clark
 
June 1995
 
BODY MASS, AND LIPID METABOLISM IN MICE WITH NONINSULIN
DEPENDENT DIABETES MELLITUS
A Thesis
Presented to the
Faculty of
California State University,
San Bernardino
Catherine R. Clark
June 1995
Approved by:
Richard Fehn, Uhair, Biology
Klaus Brasch
Date
ABSTRACT
 
The effects ofthyroid hormone on oxygen consumption rates, body mass,and lipid
 
metabolism in C57BL/KsJ diabetic and normal mice were studied in animals treated with
 
0, 100,200,or 500 ng T3/g body weight(BW)for nine days. Baseline total oxygen
 
consumption rates ofdiabetic mice were28% greater than normal mice while, after
 
receiving 500 ng Tg/gBWfor 10 days,the rates ofdiabetic animals were41% greater than
 
normal mice. The maximal increase in specific oxygen consumption rates wasfound to be
 
20%for normal mice and 52%for diabetic mice. While baseline specific oxygen
 
consumption rates ofdiabetic mice were39%lower than normal animals, Tj-stimulated
 
diabetic mice had rates that were only 19%lower than normal. Untreated and vehicle-

treated control normal mice show a decrease in specific oxygen consumption rates with
 
increasing body mass while no correlation between these parameters wasfound in diabetic
 
mice. Following treatment with 500 ng Tj/gBW for nine days both normal and diabetic
 
mice exhibited specific oxygen consumption rates that decreased with increasing body
 
mass. These results were intermediary to what was seen without T3 and both normal and
 
diabetic mice now showed similar scaling relationships. This suggests that differences in
 
specific oxygen consumption rates are due to Tg-responsive elements..
 
Lipid metabolism was also evaluated and diabetic mice showed a dose-dependent
 
reduction in serum triglyceride concentrations while no decrease was exhibited by the
 
normal animals. While VLDL and LDL were not quantified their concentrations appeared
 
to remain relatively constant in all study groups. Serum HDL concentrations ofthe
 
diabetic animals, however,were significantly greater than those ofthe normal animals at
 
hi
 
all doses ofT3 and the concentration ofHDL declined linearly with increasing doses ofT3.
 
Diabetic animals exhibited a dose-dependent rediiction in body mass while normal animals
 
showed no loss.
 
This project showed that diabetic mice are relatively resistant to T3. Differences in
 
specific oxygen Consumption rates between untreated normal and diabetic mice are not
 
due to a metabolic scaling phenomenon. It appears that a T3-responsive element, probably
 
related to the lean body mass or metabolically inactive adipose tissue, is responsible for the
 
differences observed in specific oxygen consumption rates between normal and diabetic
 
mice. While T3induced a dose-dependent decrease in body mass in diabeticmice,the
 
decline in serum triglyceride and HDL concentrations suggests reduced secretion of
 
lipoproteins. The body mass loss, however,likely reflects loss offat depositsfrom
 
adipocytes due to increased fatty acid mobilization in response to increased energy
 
consumption under the influence ofT3 stimulation.
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CHAPTER ONE:INTRODUCTION
 
Diabetes mellitus is a genetically determined disease ofglucose tolerance and handling
 
which affects 5-6% ofthe United States population and is one ofthe leading causes of
 
death and disability in the United States(1). In addition, diabetes exacts a high toll in
 
terms offinancial costs by consuming one in seven health care dollars(estimated at $105.2
 
billion per year)(2)due to frequent physician and hospital visits. Diabetes mellitus is
 
broadly classified as either insulin dependent diabetes mellitus or noninsulin dependent
 
diabetes mellitus(shown schematically in Appendix I). Insulin dependent diabetes mellitus
 
(IDDM),also known asjuvenile diabetes,is theform familiar to most people. IDDM is
 
characterized by endogenous insulin levels that are negligible or absent due to pancreatic
 
hyposecretion and is the type ofdiabetes seen most often in children and young adults
 
although,the onset ofthe disease can occur at any age. Individuals withIDDM require
 
exogenousinsulin to control glucose levels(1).
 
Noninsulin dependent diabetes mellitus(NIDDM)or adult onset diabetes accountsfor
 
85% ofthe cases ofdiabetes mellitus. NTDDM is characterized by normalto high serum
 
levels ofendogenous insulin and tissue insulin resistance. The onset ofNIDDM occurs at
 
any age but increases in prevalence with age. While a majority of individuals with
 
NIDDM are also obese(1),the physiological basis ofthe obesity is unknown(3)and is the
 
focus ofthis study.
 
The C57BL/KsJ db/db diabetic mouse serves as a modelfor NIDDM. Diabetic mice
 
exhibit age-dependent onset ofthe syndrome which is characterized by hyperglycemia,
 
hyperinsulinemia,insulin resistance, and obesity(4-7). NIDDM in diabetic mice,asin
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humans,is genetically determined(I,?,8), yet the gene defect and mechanism(sjofthe
 
pathology remain undefined. Proposed defects in thyroid hormone responsiveness and
 
abnormal thyroid hormone profiles make this an interesting model with whidh to
 
investigate potential endocrine defects which may contribute to the obesity associated with
 
the development ofthe disease.
 
^Thyroid hormones have beeii shown to play major roieS in regulatidn ofdevelopment,
 
growth,and metabolism(9,10). Th^dxine(T4),a homione that is synthesized and
 
secreted by the thyroid gland,is concerted by the liver and kidney to a metabolically active
 
form ofthe hornione triiddothyronine(T3), The actidns ofthyroid hormones are mediated
 
through the binding ofthe T3to nuclear receptors located on theDNA. The receptors are
 
protein complexes which bind specific regions ofDNA to regulate gene transcription and
 
thus,the expression ofgene products(9). The regulation ofthyroid hormone-responsive
 
genes can occur through control ofgene transcription rates,the stability ofthe mRNA
 
produced,and the rate ofdegradation ofthe protein products(10). It has been suggested
 
that thyroid hormones exhibit tissue-specific regulation at all ofthese levels(9).
 
Defects in thyroid hormone responsiveness have been demonstrated in the diabetic
 
mouse modelfor NIDDM. pbese-diabetic animals exhibit higher serumT3 concentrations
 
(11,12)and lower metabolic responses to T,(13)when compared to their normal
 
counterparts. Previous studies in our laboratory(personal communication)have shown
 
that diabetic mice have a relative insensitivity to T3in that,they do not respond
 
metabolically to physiologic concentrations ofT3 but remain capable ofresponding to
 
supraphysiological concentrations ofT,(Figure 1). The reason for the failure ofthe
 
diabetic mice to respond to physiological concentrations ofT3 remains unknown.
 
However,previous studies haveshown that the binding affinity ofthe hepatic Tjreceptors
 
is decreased in stable obesediabetic aninials, 13-25 weeks ofage,when compared to their
 
normal counterparts(Figure 2). Since the nuclear T, receptors ofdiabetic animals are not
 
able to bind Tjas tightly as thoseofnormal aihmals the binding differences could lead to
 
attenuated responses due to shorter binding times and reduced gene regulation. In
 
addition,the numberofTs reiceptors is increased in obese diabetic aninials when compared
 
to the normal mice and,though the total number ofbinding sites is greater than normal,a
 
defect remains which prevents the diabetic animalsfrom responding to nonnal serum
 
concentrations ofT3. The decreased binding affinity, defective receptors, and/or a
 
post-receptor defect likely contribute to the decreased metabolic response to T3,thus
 
normal T3-regulated processes are compromised in diabetic mice.
 
Thyroid hormone has been shown to be an important regulator ofintermediary
 
metabolism. Both hepatic lipogenesis and adipocj^e lipolysis are stimulated by T,. T3
 
stimulates an increase in the transcription ofmRNAfor lipogenic enzymes such as malic
 
enzyme,glucose 6-phosphatase,and fatty acid synthase(9,14). Lipolysis in adipocytes is
 
also stimulated by T3 and this leads to the breakdown oflipids and release offatty acids
 
which may be used as an energy source for peripheral tissues(15). A synergistic
 
hormone,growth hormone(GH),is involved in the lipolytic responses and is also
 
dependent upon control by Tj. T3leads to an increase in the synthesis and secretion of
 
pituitary growth hormone(GH)(16,17). Growth hormone,in turn, plays a permissive
 
role to TjAnduced lipolysis in adipocytes(18). Paradoxically, while T,induces hepatic
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Figure 1. Dose-response curve for relative increasesin specific oxygen consumption rates
 
ofnormal(•-•)and diabetic(0-0)mice treated on nine consecutive days with varying
 
doses ofT3. Diabetic animals attain a maximal response at 500 ngTJgBW that was
 
150% above basal levels while the normal animals attain a maximal response at 200
 
ng Tj/gBW(40% above basal)and show no further increase. Values are mean+SEM,
 
n=3(Fehn and Lang,unpublished observations).
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Figure 2. Scatchard plot ofhepatic T3receptors ofnormal(0-0)and diabetic(•-•)mice
 
where the intercept with the abcissa indicates the approximate number ofbinding sites and
 
the slope ofthe line indicates the binding affinity. Diabeticmice have a decreased binding
 
affinity for T3 and a greater number ofbinding sites in the hepatocyte compared to normal
 
mice.
 
lipogenesis it also induces the growth hormone which is necessary to allow adipocytes to 
respond to Tj-induced lipolysis(shown sehematically in Appendix II). Thus,T3 playS a 
role in both lipogenesis and lipolysis. y ■ 
Alterations in lipid metabolism have been demonstrated in the C57BL/KsJ diabetic
 
mouse. Diabetie mice have been shown to have high serum triglyceride and cholesterol
 
levels. It has been hypothesized that the elevated triglyceride levels ard due to increased
 
secretion oftriglycerides from the liver and/or arlefect in the clearance oftriglycerides
 
from the blood. In addition, it has been proposed that the basal rate oflipolysis in
 
adipocytes ofdiabetic animals is increased(8).
 
Part ofthe altered lipid metabolism seen in diabetic mice may result from attenuated
 
Tj-induced, GH-dependent lipolysis in adipocytes which results from suppression of
 
pituitary GH synthesis(19)and secretion due to the increased concentrations ofinsulin
 
normally present in these animals. Prager et al(16)have demonstrated that insulin
 
suppresses Tj-stimulated GH mRNA levels in vitro. Suppression ofGH was apparent 24
 
hours after the addition ofsupraphysiological concentrations of insulin to rat pituitary
 
tumor cells and did not decrease until 96 hoursfollowing the removal ofthe insulin(16).
 
Since GH is necessary to prime the adipocyte for Tj-responsive lipolysis to occur,the
 
blunting ofthis response by hyperinsulinemia may partially account for the obesity seen in
 
diabetic mice.Ifthe rates ofhepatic lipogenesis and storage oflipids in adipocytes remain
 
normal while the release oflipids from adipocytes is decreased due to GH deficiency-

induced thyroid hormone-insensitivity this could lead to net fat deposition and contribute
 
to the development ofobesity. Tissue-specific alterations in Tj-responsiveness therefore.
 
could help explain this phenomenon.
 
This research project was designed to study,in diabetic mice, metabolic responses to
 
T3 by measuring oxygen consumption rates as an indicator oftotal energy metabolism and
 
by evaluating the effects ofTjtreatment on lipid metabolism through the analysis ofserum
 
tfiglyceride and Serum verylow density lipoprotein(yLDL),low density lipoprotein
 
(LDL),and high density lipoprotein(HDL)levels. In vivo oxygen consumption using a
 
flow-through oxygen analyzer was also employed because it offers a convenient and
 
noninvasive techniquefor measuring metabolic rates in intact animals.
 
Since T3 plays a major role in stimulating metabolism,increased levels oftjwould be
 
expected to lead to increased energy utilization and hence increased oxygen consumption
 
rates, as has been demonstrated previously in obese mice(20). The increased metabolic
 
rates should reflect the increased demandsfor energy, which may be met by available f f
 
glucose via glycolysis and in subsequentlong-term demands by glycogenolysis. When the
 
glycogen stores are depleted however,a conversion to lipid metabolism should occur.
 
VLDL serves to transport lipidsfrom the liver to other tissues and,thus,the levels of
 
serum VLDL would be expected to increase under increased energy demand. However,it
 
is important to note that as the VLDL releases its lipids it is converted,into LDL which
 
may cause serum VLDL concentrations to decrease. Most likely the serum LDL
 
concentrations would be expected to decrease since LDLsbind to receptors and are then
 
internalized and degraded by muscle, mammary,adipose,and steroidogenic tissues to
 
supply cells with cholesterol(21). In addition,serum HDL concentrations would be
 
expected to decrease or remain stable sinceIIDL does not serve as a source offuel but
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rather as a cholesterol transport molecule.
 
It is the intent ofthis study to compare Tj-assqeiated metabolic responses in normal
 
and diabeticmice to determine whether there are interphenotypic differences and to
 
deteimine ifT3treatment leads to intraphenotypic changes in lipid metabolism.
 
CHAPTERTWO:MATEMALS
 
Animals
 
C57BL/KsJ homozygous db/db diabetic and heterozygous db/m normalmice were
 
obtained from the Jackson Laboratories(Bar Harbor,Maine). The animals were housed
 
at 23 C,40-60% humidity,and 14L:10P lighting, lights were onfrom 0600to 2000 hours,
 
in shoebox cages containing hardwood chip bedding. Tek Lab4%rodent chow and water
 
were provided ad libitum. ^
 
Eight- to ten-week old animals received daily intraperitonealinjeptious df; ■ : 
L-3,5,3'triiodothyrohine, T3(Sigma Chemical Company#T2877)in the following doses; 
100,200,and 500 ng/g body weight. The T3was prepared daily using 100 ug/ml in 0.5 
mM NaOH. Control animals received intraperitoneal injections ofvehicle(0.5 mM 
NaOH)in proportional volumes(2ul/g BW). Each experimental group consisted offive 
db/db diabetic and five db/m normal animals. Injections were given between 0800 and 
1200 hours for nine consecutive days(day 1 through 9)following metabolic readings(see 
Oxvaen Consumption
 
The oxygen consumption ofeach experimental animal was measured by an Amtek
 
S-3A/TI Oxygen Analyzer,at aflow rate of140 ml per minute(as determined by Gilmont
 
Flowmeter D-665). Ten minute readings were taken on all animals on days 1 through 10
 
between 0700 and 1145 hours. Animals were\yeighed daily for specific oxygen
 
consumption determinations and possible weight changes. Totalin vivo metabolic
 
responses to Tjwere reported as total oxygen consumption(ml Oj• min'-), specific
 
oxygen consumption(ml O,'g"''nnn^)/and percent increase in specific oxygen
 
consumption above baseline levels. AH animals were evaluated in the nonfasting state.
 
The data were subjected to analysis ofvariance(22)and compared by Duncan's Multiple
 
Range Test(23).
 
Blood Collection and Analvsis
 
All mice were sacrificed by CO2euthanasia on day 10 starting at 1330 hours. Blood
 
was collected by cardiac puncture using a 23 gauge needle on a 1.0 ml syringe. Samples
 
were placed in microtainer serum separator tubes(Becton Dickinson)and then
 
refiigerated at4C until clotted. The samples were then centrifuged at 1700 x g for40
 
minutes at4 C. Recentrifligation was conducted on samples when necessary. The serum
 
was allquoted into 1.5 ml microcentrifuge tubes in the following manner: 100 ul for serum
 
HDL determinations and 20 ul for serum triglyceride determinations. All samples were
 
Stored at4C until assayed.
 
Serum concentrations ofVLDL,LDL,and HDL were determined using the REP
 
Ultra-30HDL,VLDL/LDL Cholesterol electrophoresis system. This system uses an
 
agarose gel to separate serum lipoproteins by molecular weight. The amount of
 
cholesterol and cholesterol esters present in the sample are directly proportional to the
 
enzymatic degradation by cholesterol esterase(24). The electrophoresis was performed
 
BytomaLinda University Medical Center Clinical Laboratory. Relative quantitation of
 
the samples,using a photoimiage ofthe gel,was perfbtmed'iising aSICiR^ 62Q
 
Video Densitometer. Data are reported in optical density units.
 
Serum triglyceride levels were determined by commercial assay(Sigma Chemical
 
Company#339)using a colorimetric determination involving enzymatic degradation by
 
lipoprotein lipase. Percent transmittance was read at 550 nm on a microtiter plate reader
 
(BioKinetics Reader EL312e). Data are reported as mg/dL.
 
Data were subjected to analysis ofvariance and compared by Duncan's Multiple Range 
Test. ■ ­:J; 'U
 
Percent Bodv Fat
 
Body weights ofthe dead mice were measured in air and in water using a Scientech
 
5500top loading balance. Mice were suspended from an alligator clip for measurements
 
in air. The suspended mice were then submerged in a IL beaker containing water,
 
massaged to release air trapped in their lungs and fur, and weighed again. The
 
temperature ofthe water was recorded for water density corrections.
 
The Siri equation(25)was used to calculate the density ofthe mouse body:
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 M3XD^
 
■..where:,;
 
Ma= mass ofmouse in air -­
= rnass ofinouse in water
 
RV=residual lung volume 
The value used for theRV was0.5 ml as determined by Rudrich and Fehn(26). The 
percent body fat was calculated as(25): 
. 495 . ■ 
%body fat- -450 
The data were subjected to analysis ofvariance and compared by Duncan's Multiple
 
The livers ofboth diabetic and normal mice were excised following COjeuthanasia and
 
the nuclei were isolated by homogenizing the liver in STM(0.32M sucrose,3 niM MgCf,
 
0.5% Tween). The samples were then centrifuged 10 minutes at 800 x g at4 C. Samples
 
were aspirated to remove the supernatant. Nuclear pellets were washed in STM, ^
 
centrifuged,and aspirated two times. The nuclei were then resuspended in SM(0.32M
 
sucrose,3 mMMgCl,). The nuclei were divided into ten samples. Five concentrations of
 
1-125 labeled Tj(NEN Research Products, 1200 uCi/ug)(2.2 x 10'^,6.6 x 10"'",
 
6.6 X lO'^V 6.6 X 10"'^,6.6 x 10"^^ M in 400mM KCl)were added to these preparations.
 
The samples were incubated overnight at4Cto permit hormone-receptor complex
 
formation. Supernatants were aspirated and the amount ofT3bound to the receptors was
 
determined using a scintillation counter(Picker Pace-1). The amount ofDNA present in
 
each sample was determined using the diphenylamine assay(27). The data obtained were
 
used to generate Scatchard plots(28). Tissue samples were grouped into young(5-6
 
weeks ofage;n=2),stable(13-25 weeks ofage;n=4for normal and n=5 for diabetic
 
mice),and old(54 weeks ofage;n=l). Data were subjected to analysis ofvariance and
 
Duncan's Multiple range test.
 
CHAPTER THREE:RESULTS
 
Themetabolic responsesfollowing nine days oftreatment with various doses ofT3 are
 
shown in Figure 3. Normal animals receiving 500 ng T3/gBW exhibited a maximal
 
increase of20%in specific oxygen consumption above vehicle-treated normal control
 
animals that received 0ng T3/g BW.The maximal increasein specific oxygen consumption
 
for the diabetic animals receiving 500 ng T3/gBW was52%greater than vehicle-treated
 
diabetic control animals. The percent increase in specific oxygen consumption rates in
 
response to the maximum dose ofT3is therefore 2.6 times greater in diabetic than in
 
nondiabeticmice.
 
The changes in total oxygen consumption over the ten days ofobservation are shown
 
in Appendix III and graphically in Figure 4. In both the normal and diabetic animals,total
 
oxygen consumption rates were maximal on day6,increasing64% and 47% above
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Figure 3. Dose-response curve for relative increases in specific oxygen consuniptionfates
 
ofnofmal(0-0)and diabetic(•-•)mice treated for nine days with varying doses ofT3.
 
Diabetic animals show a maximal increase of52% while the maximal increase in normal
 
animals was20%. Values are mean-mean ofvehicle-treated control animals, n=5.
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Figure 4. Daily total oxygen consumption rates ofnormal(0-0)and diabetic(•-•)rnice
 
during nine daysoftreatment with 500 ng Tj/g BW. Day one fepfesents baseline leyels
 
prior to initial injections after which treatments were administered daily. Baseline total
 
Diabetic mice attain rates that are41% greater than nomial animals on day 10. Diabetic
 
animals plateau at day6while the normal animals attain mammal ra;tes on day6 and then
 
decline. Values are mean+SEM,n=5.
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baseline levels, respectively. Each wasfollowed by a gradual decline such that, on the
 
tenth day ofthe experiment, oxygen consumption rates were only29% and 41% above the
 
baseline levels(day 1)for normal and diabetic animals, respectively. The diabetic animals
 
consistently had greater total oxygen consumption rates than the normal animals, as might
 
be expected since the diabetic animals are approximately twice the body mass ofnormal
 
animals.
 
In contrast,the mass-specific metabolic rates show that obese-diabetic animals 
consumed 39%less oxygen per gram oftissue than the normal animals on the tenth day 
(AppendixIV and shown graphically in Figure 5). The specific oxygen consumption rates 
for normal animals rosefrom 0.049 ml O2'g"'' min'^ to a maximum of0.082 ml 
O2 ■ g'^ ■ min"'at day6 and then declined to 0.062 ml O2'g 'min"^ by day 10. The 
diabetic animals however,showed consistent daily increases in specific oxygen 
consumption ratesfrom 0.030 ml O2'g"^' min'^ to 0.050 ml O2'g"^'min ^ over the full ten 
days ofstudy. 
Evaluation ofthe dose-dependent responses to T3induction ofmetabolism using total
 
(Figure 6)and specific(Figure 7)oxygen consumption rates for the normal animals on day
 
6ofthe experiment showed that rates did not change significantly from 0 ng Tj/gBW to
 
100 ng T3/gBW nor from0ng T3/gBW to 200 ng T3/gBW dose. The total and specific
 
oxygen consumption rates for normal mice receiving 500 ng T3/gBW however,increased
 
(p<0.01)above that seen in the0,100,and 200 ng Tj/gBW animals. When diabetic
 
animals receiving0ng T3/gBW were compared to T3-treated diabetic animals,initial
 
increases in total and specific oxygen consumption rates were evident at 100 ng Tj/gBW
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Figure 5. Specific oxygen consumption rates ofnormal(0-0)and diabetic(•-•)mice
 
receiving daily injections ofT3(500 ng/gBW)over a ten day period. Day one represents
 
baseline rates prior to initial injections after which treatments were administered daily.
 
Baseline specific oxygen consumption rates ofdiabetic animals are 39%lower than normal
 
animals. On day6the specific oxygen consumption rates ofdiabetic animals are43% less
 
than normal while on day 10the rates ofdiabetic animals are only 19% less than normal
 
animals. Diabetic animals show a linear increase in specific oxygen consumption rates
 
while the normal animals attain maximal rates on day6 and then decline. Values are mean
 
±SEM,n=5.
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Figure 6. Dose-dependent changes in total oxygen consumption rates ofnormal(0-0)and
 
diabetic(•-•)mice receiving daily injections ofT3(0, 100,200,or 500 ng/g BW)over a
 
six day period. The increases are similar for both diabetic and normal mice, however the
 
absolute values are greater for diabetic animals than for normal animals at all doses
 
(p<0.01). Values are mean±SEM,n=5.
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Figure 7. Dose-dependent changes in specific oxygen consumption rates ofnormai(0-0)
 
and diabetic(•-#)mice receiving daily injections ofT3(0, 100,200,or 500 ng/gBW)over
 
a six day period. The increases are similar for both diabetic and normal animals,however
 
the absolute values for the diabetic mice are lower than those ofthe normal animals at all
 
doses(p<0.01). Values are mean±SEM,n=5.
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(p<0.05),no changes wereobserved at 200 ng Tj/gBW,and then substantial increases
 
occurred at 500 ng Tj/gBW(p<0.01). It is noteworthy that while the total and specific
 
oxygen consiimption rates ofdiabetic and normal animals were statistically distinguishable
 
(p<0.01)at all doses,the slopes ofthe lines were similar for both groups(m=0,037for
 
normal and m=0.038for diabetic; m=0.001 for normal and m=0.002for diabetic for total
 
and specific oxygen cohsurnption fates, respectively). This suggests that the
 
dose-response to Tjis similar in bpth diabetic and normal riiice. The set point however, is
 
lowerfor specific oxygen consumption rates in diabetic mice than in normal mice.
 
The totaland specific oxygen cbnsumptioh rates for both normaland diabetic animals
 
on thetenth day ofthe experiment are shown in Figures8 and 9,respectively. The normal
 
animals had totaland specific oxygen consumption rates that were not significantly
 
different from0ng Tj/gBW to 100 ng Tj/g BW. However,when compared to the0ng
 
Tj/gBW treatment,the normal animals showed significant increases in both total and
 
specific oxygen consumption rates at 200 ng Tj/gBW(p<0.05)and at 500 ng T^/gBW
 
(p<0.01). The diabetic animals,on the other hand,exhibited significant increases in total 
and specific oxygen consumption rates at all doses ofTjwhen compared to the 
vehicle-treated (0 ng Tj/g BW)control diabetic animals(p<0.01). Interestingly,in 
contrast to above,the slopes ofthe lines are no longer similar for the diabetic and normal 
mice. The slope ofthe oxygen consumption rates for the diabetic mice(m=0.090for total 
and m=0.003 for specific)is greater than the slope for the normal mice(m=0.045 for total 
and m-0.001 for specific)suggesting that the dose-response is greater in the diabetic 
mice. . ' .'TT ^ ■ 
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Figure 8. Dose-dependent changes in total oxygen consumption rates in nprmal(0-0)and
 
diabetic(•-•)mice receiving daily injectionsofT3(0, 100,200,or 500 ng/g BW)over a
 
ten day period. Diabetic animals show a greater increase than normal animals(p<0.01).
 
Values are mean+SEM,n=5.
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Figure 9. Dose-dependent changes in specific oxygen consumption rates in normal(0-0)
 
and diabetic(•-•)liiice receiving daily injections ofT3(0, lOO^ 200,or 500 ng/gBW)over
 
a ten day period. Diabetic animals show a greater increase than normal animals,but
 
diabetic animals have specific oxygen consumption rates that remain lower than normal
 
animals(p<0.01). Values are mean±SEM,n=5.
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Normal mice showed no significant change in body mass(g)from day 1 through day 10
 
in any ofthe treatment groups(Figure 10). In contrast,the diabetic animals showed
 
significant dose-dependent decreases in body mass at all doses off,when compared to
 
mass at
 
In order to study the relationship between body mass and specific oxygen
 
consumption rates, first order regression curves were generated for these two parameters.
 
Normal mice, prior to the initial injections ofT3, had specific oxygen consumption rates
 
that decreased asthe body massincreased as is typically observed(m=-0.369)(23)
 
(Figure 11). The slope ofthis regression was similar to that ofuntreated normal mice
 
having a wider range ofbody masses(data not shown). In contrast, in diabetic mice, prior
 
to initial T3 injections, specific oxygen consumption rates were similar for all body masses
 
(m=0.031), A lack ofvehicle effect was confirmed in that normal mice receiving0ng Tj/g
 
animals(m=-0.375)(Figure 12). The diabetic mice again did not show changes in
 
specific oxygen consumption rates relative to body mass(m=0.013).The specific oxygen
 
consumption rates ofdiabetic animals therefore, do not appear to be influenced by the
 
To determine whether the magnitude ofTj-induced metabolic responses might be a
 
direct function ofbody mass,first-order regression curves ofspecific oxygen consumption
 
rates versus body massfor normal and diabetic mice receiving 500 ng Tj/gBWfor ten
 
days were generated(Figure 13). At this dose ofT,both the normal and diabetic mice
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Figure 10. Dose-dependent weight loss in normal(0-0)and diabetic(•-•)mice receiving
 
daily injections ofT3(0, 100,200,or 500 ng/g BW)over a ten day period. Diabetic
 
animals show a dose-dependent reduction in body weight compared to vehicle-treated
 
controls(p<0.01)while normal animals show no loss(p>0.05). Values are mean±SEM,
 
n=5.
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Figure 11. First order regression curve ofspecific oxygen consumption rates at various
 
body masses(g)ofnormal(0-0)and diabetic(•-•)mice on day one prior to initial
 
injections ofT3. Normal animals show a decrease in specific oxygen consumption rates as
 
the body mass(g)increases. However,the diabetic animals had specific oxygen
 
consumption rates that were not in proportion to total body mass(g).
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Figure 12. First order regression curve ofspecific oxygen consuraption versus body mass
 
(g)ofnormal(0-0)and diabetic(•-•)mice receiving daily injections ofvehicle(2 ul/g
 
BW)over a ten day period. Normal aninials show a decrease in specific oxygen
 
consumption rates as the body mass(g)increases. The diabetic animals however, did not
 
show any changes in the specific oxygen consumption rates as the body mass(g)
 
increased.
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Figure 13. Regression curve ofspecific oxygen consumption rates at various body masses
 
(g)ofnormal(0-0)and diabetic(•-•)mice receiving daily injections of500 ng T3/gBW
 
over a ten day period. At this dose ofT3the normal and diabetic animals both exhibit
 
specific oxygen consumption rates that decrease as the body mass(g)increases. Both
 
exhibit responses that are intermediate to untreated animals and now have the same
 
relationship.
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were fully stimulated metabGlically and both had specific oxygen consumption rates that
 
decreased as the body mass increased(m=-0.067for normal and m=-0.073 for diabetic
 
animals). These results were intermediate to what had been observed in normal and
 
diabetic mice receiving0ng T3/gBW and both groups were now on the same scaling
 
curve. This clearly shows that metabolic responses are different in vehicle-treated diabetic
 
mice when compared to vehicle-treated normal mice but, are more uniform -with Tj
 
treatment.
 
Serum triglyceride levels were analyzed to assess lipid mobilization in response to T3
 
(Appendix V and shown graphically in Figure 14). The serum triglyceride levels in
 
normal animals remained constant at all doses ofT3 relative to the vehicle-treated(0 ng
 
Tj/gBW)normal control animals(p>0.05). Interestingly, thyroid hormone treatment
 
significantly lowered serum triglyceride concentrations in diabetic mice at all doses ofT3in
 
a dose-dependent manner when compared to the vehicle-treated diabetic control animals.
 
Diabetic animals that received T3 at doses of100,200 and 500 ng/gBW had triglyceride
 
levels that decreased by 38%,29%,aiid 41%,respectively, when compared to diabetic
 
animals receiving0ng T3/gBW. The serum triglyceride levels ofthe diabetic mice were
 
consistently elevated compared to those ofthe normal mice(p<0.01)..
 
Serum profiles ofVLDL,LDL,and EDDL were attempted to assess lipid mobilization
 
and transport(Figure 15). The gel system did not provide quantifiable images ofVLDL
 
orLDL due to very light staining ofthese bands. TheHDL banding,however, was clear
 
and therefore subjected to quantification by densitonietry(Appendix VIand show
 
graphically in Figure 16). The diabetic animals that received vehicle only have a
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Figure 14. Regression curve ofdose-dependent decrease in serum triglyceride
 
concentration in normal(0-0)and diabetic(•-•)mice receiving daily injections ofT3(0,
 
100,200,or 500 ng/g BW)over a ten day period. Diabetic animals show a reduction in
 
serum triglyceride concentration(p<0.01)while normal animals show no change(p>0.05).
 
Values are mean+SEM,n=5.
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Figure 15. Agarose gel ofserum lipoproteins in 75 ul serum samples collected from
 
nonfasting normal and diabetic anim (0, 100,or 200 ng/g
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scan ofgel shown in Figure 15. Dose-dependent decrease in serum HDL concentration in
 
normal(0-0)and diabetic(•-•)mice receiving daily injections ofT3(0, 100, or 200 ng/g
 
BW)over a ten day period. Diabetic animals show a linear decrease in serum HDL
 
concentration(p^O.Ol)while normal animals show a decrease from 0 rig T^/gBW to 100
 
ng T3/gBW(p<0.01)and no further change from 100 ng T3/gBW to 200 ng T3/gBW
 
(p>0.05). The serum HDL concentrations ofthe diabetic ariiirials are greater than those of
 
the riorrnal animals at all doses ofT3(p<0.01). Values are mean±SEM,n=5 except
 
normal200 ng/gBW where n=4.
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significantly higher concentration ofsemm HDL which approaches six times that oftheir
 
normal counterparts(pgO.Q1), A dose-dependent reduction in HDLis apptarent in that
 
normal animals exhibited a sigraficant decrease in serum HDL concentrationsfrom0ng
 
Tj/gBWto 100 ng 1-^1gBW (p<0.01)and from0ng Tg/gBW to 200 ng Tj/gB\V
 
(p<0.01),but did not exhibit a significant changefrom 100 ng Tj/gBW to 200 ng Tj/g
 
BW(p>0.05). A linear decrease in HDLconcentrations was observed in diabetic ariimals
 
with increasing doses ofTj(p<0.01). Although a decrease in HDLconeentratipns is seeh
 
in both the normal and diabetic animals at 100 and 200 ng Tj/g BW doses when compared
 
to vehicle-treated control animals,theHDL concentrations ofthe diabetic animals remain
 
greater than those ofthe normal animals(p<0.01). The serum HDL concentrations ofthe
 
500 ng Tj/gBW normal and diabetic animals were not obtained.
 
An analysis ofbody composition(%bodyfat)was performed to determine whether
 
increased metabolic demands were coupled with selective decreases in fat, presumed to be
 
used as a fuel source. The percent body fat ofthe normal mice significantly increased at
 
100 ng T3/gBW(p<0.01)but showed no significant change at 200 ng T^/gBW and 500
 
ng Tj/gBW(p>0.05)when compared to the vehicle-treated control animals(Table 1).
 
The diabetic animals,on the other hand, exhibited a significant decrease at 100 ng Tj/g
 
BW(p<0.01),showed no significant change at 200 ng Tj/gBW(p>0.05),and again
 
exhibited a significant decrease at 500 ng Tj/g BW(p<0.05)when compared to
 
vehicle-treated control animals. In normal animals,low doses ofTjappear to either
 
induce fat deposition or reduce lean body mass while high doseslead to no
 
disproportionate changes in composition. Diabetic animals,on the other hand,show
 
 
 
 
Table 1. Percent body fat presented as mean±SEM,n=5.
 
■:; j lOQ,. ; : .20oH-" ' - .500 - ;/' ■ ■ ■■. ■ 
ngTj/gBW .ngTj/gBW : ng Tj/gBW ngTj/gB# 
NORMAL 22.70 ± 0:90 24,58± 1.01 :23:i4 +1.43+': ::22:i:3+ LOT 
DIABETIC 36.l7±i.Il 34.60 + 0.93 ; ; 35.52 ± 0 20 ■ 3^.9T± 0.56+: 
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reductions in fat composition with increasing doses ofT3 except at the 200 BW
 
dose. The normal mice consistently had alower percent body fat(23.14+0.55%,n=5)
 
than their obese-diabetic counterparts(35.30+0.38%,n=5).
 
Assessment ofhepatic T3 receptors was performed to provide a possible explanation
 
for thyroid hormone resistance seen in diabetic mice. The total amount ofT3 bound to the
 
receptor wasfound to be age- and phenotype-dependent(Table 2). Young diabetic mice
 
(5-6 weeks ofage)had less T3 bound to the receptors than the young normal mice. The
 
stable diabetic mice(13-25 weeks ofage)and old diabetic mice(54 weeks ofage)had
 
more T3 bound to the receptors than their normal counterparts. The approMmate maximal
 
binding capacity(MBC)for the high affinity,low capacity(functional)receptors exhibited
 
the same pattern with the diabetic young mice having a decreased MBC while diabetic
 
stable mice and diabetic old mice had an increased MBCcompared to their normal
 
counterparts. The Kd,50 percent saturation ofthe binding ofa hormOne to its receptor,
 
wasfound to bejust the opposite ofthe above. The young diabetic inice had an increased
 
Kd while the stable and old diabetic mice had decreased Kds when compared to their
 
normal counterparts.
 
CHAPTERFOUR: DISCUSSION
 
Previous studiesin this laboratory have shown that it was possible for adult diabetic
 
animals(30-60 weeks ofage)to attain total and specific oxygen consumption rates of
 
normal magnitude when given sufficiently high concentrations ofT3(500 ng/gBW)for ten
 
days. These results indicate that the T3-responsive processes in the obese-diabetic animals
 
Table 2. Characterization ofhepatic thyroid hormone receptors.
 
NORMAL DIABETIC
 
YOUNG STABLE OLD YOUNG STABLE OLD 
(5-6 (13-25 (54 (5-6 (13-25 (54 weeks 
weeks weeks weeks weeks of weeks of ofage) 
ofage) of age) ofage) age) age) 
Total 
Binding 3422 4612 2262 1894 6660 2454 
(cpm/ug 
DNA) 
Maximal 
Binding 
Capacity 14 21 11 9 28 16 
(fmol/mg 
DNA) 
Kd 
(fmol/mg 7 8 6 4.5 10 9 
DNA) 
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are preserved and that diabetic animals are relatively, not absolutely, insensitive to T3
 
In the present study the young diabetic animals(8-10 weeks ofage)approach,but
 
never attain total and specific oxygen consumption ratesofnbrmatmagnitude. However,
 
the changes seen in both the normal and diabetic animalsin this study were ofa leSser
 
magnitude than those observed in the older mice used in the previous study. Possible
 
explanationsfor this discrepancy rriay be age-dependent physiologicaldifferences^ changes
 
in body composition with age or simply differences in mass, the initial masses ofboth the
 
normal and diabetic adult aninials used in the previous study(26.65±0.63 g vs. 48.91+
 
1.72 g,respectively)were significantly higher than those ofthe normal and diabetic young
 
animals ofthis study(21.81 ±6.29g vs. 46.35+0.67 g,respectively; p<0.01), Ifthe .
 
discrepancy was due simply to massthen direct comparisons ofoxygen consumption rates
 
between age groups and phenotypes would be compromised.
 
Vertebrate animals have been shown to have specific oxygen consumption rates that
 
decrease as the mass ofthe animalincreases(29). This is typically attributed to the
 
proportionately smaller surface areafelative to body volume which reduces environmental
 
exchanges hence,the lower energy expenditures. Diabetic mice,were found to have mass-

specific oxygen Consumption rates that were about halfthat ofnormal animals and two 

possible explanations can be prpposed for the differences. First, ifthe differences in the
 
specific oxygen consumption rates between normal and diabetic animals were simply due
 
to the differences in body mass and proportional surface area then,according to
 
extrapolation from the regression curve(Figure 13), a22g diabetic mouse should have a
 
predicted specific oxygen consumption rate comparable to a 22g normal mouse. This is
 
I 
not the case. Diabetic anirnals ofthis mass would have a predicted specific oxygen
 
consumption fate ofapproximately 0.020 ml Oj g"' niin'Vwhich isclearlylower than the
 
measured specific oxygen consumption rate of22g normal animals(0.050 ml 
O2 ■ g'- niin^). Thus,it appears that the differences in oxygen:consumption rates are not 
due to a scaling phenomenon but rather an alteration in some physiological mechanism; 
The observation,that maximal stimulation ofdiabetic and normal mice(with 500 ng T/g 
BW for ten days)led to a scaling relationship in metabolic response that wasintermediate 
to those observed in untreated animals,suggests that the mechanism responsible for the 
observed differences between phenotypes and ages is Tj-responsive. In addition,these 
results suggest that the Tj-respOnsive element is related to the lean body mass(30)or to 
the activation ofpreviouslydnactive adipose tissue, . ( - ; ■ 
Although the changes in body mass were veiy similar in both old and young mice,the
 
magnitudes ofmetabolic increases seen with T3 treatment were quite different. Neither
 
young nor old normal animals exhiNted a;significant change in body mass at any dose of
 
T3. Conversely,the adult diabetic animals had a loss in mass that approached 20%while
 
the young diabetic animals similarly approached a 17% loss in mass at 500 ng Tj/gBW.
 
There does not appear to be an age-dependent difference in T3 effect on the loss ofbody
 
mass. This supports the idea that the metabolic differences were not due to differehces in
 
total body mass since alterations in body mass do not occur in normal animals and occur in
 
diabetic animals but, both exhibit increases in oxygen consumption rates with T,
 
treatment. In addition, this suggests that the difference in the magnitude ofincrease in
 
specific and total oxygen consumption rates observed between age groups may be due to
 
the ability ofthe animals to compensate for the increased T,levels from exogenous
 
sources. Another possible explanation is, ifthe increased oxygen ppnSumption rates are
 
due to the activation ofadipocytes, older animals have proportionately more fat and thus
 
cotild have increased fatty acid mobilization to a greater degree in response to increased
 
energy consumption.
 
The young animals in this study were at the stage in development where the serum T3
 
levels arejust starting to stabilize while the serum T3 levels in the adult animals used in the
 
previous study had been stabilized for some time(Figure 17). The T3resistance that is
 
associated with NIDDM may still be developing in the young animals thus allowing
 
them to regulate their metabolic responses to the varying doses ofT3. However,it is
 
likely that the T3 resistance is fully established in the older animals limiting the amount of
 
regulation they can achieve. The ditferences in the levels ofT3 resistance between the old
 
mice and the young mice may be due to changing receptor populations as has been shown
 
in this lab(Table 2). The old diabetic mice had hepatic T,receptor populations
 
that most closely resembled the normal mice and thus,could be expected to respond in a
 
similar fashion metabolically when stimulated maximally by exogenous T,. The young
 
diabetic mice,on the other hand, had fewer hepatic thyroid hormone receptors than the
 
young normal mice which could render them,even though they received the same
 
maximum dose ofT3 as the old mice,unable to respond to the same degree. Thus,it
 
appears that the metabolic responses to T,are age-dependent.
 
Physiological sensitivity to T,was evaluated by using dose-response curves ofT3­
stimulated increases in oxygen consumption rates in normal and diabetic mice. The 100
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Figure 17. Nonfasting serum Tjconcentrations ofnormal(•-•)and diabetic(0-0)mice at
 
various ages. The Tjconcentrations ofdiabetic animals(233±39 ng/lOOml,n=50)are
 
greater than those ofnormal animals(201 +40 ng/100 ml,n=127;p<0.05). Values are
 
mean±SEM(19).
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ng/gBW dose ofTjrepresents replacement ofthe normal physiQlogicalconcentration of
 
Tj. Normal mice at 100 ng/gBW T,likely decrease the amount ofendogenous T3
 
produced in response to the addition ofexogenousT,and therefore,these animals are not
 
exposed to increased levels ofT3. The oxygen consumption rates on day6 reflect this
 
since they are not significantly different from the oxygen consumption rates ofthe
 
vehicle-treated control amrnals. Atthe same dose and time the diabetic animals however,
 
show an increase in oxygen consumption rates and this serves to emphasize the ditferential
 
responsiveness in these animals. This may occur because the 100 ng/gBW dose ofT3
 
raises the already elevated levels ofendogenous T3to achieve a supraphysiologica!dose
 
allowing the animals to respond metabolically. The 200 ng/gBW dose ofT3is the first
 
supraphysiologic dose ofT3used in this study. Neither normal nor diabetic animals show
 
a significant change in oxygen consumption rates at 200 ng/gBW when compared to the
 
animals that received 0 ng/gBW. This was an unexpected result, but it appears that both
 
the normal and diabetic animals undergo a rebound phenomenon in responsiveness and
 
therefore, no changes occur in the oxygen consumption rates. This rebound phenomenon
 
may be due to down regulation ofT3 receptor populations and/or decreased levels of
 
thyroid stimulating hormone(TSH)which would lead to decreased production of
 
endogenousthyroid hormones. Brent et al(31)have shown that the maximum reduction
 
in receptors is20%thus,down regulation ofthyroid hormone receptors by itselfcan not
 
explain the rebound phenomenon. Another possible explanation for the unchanged
 
oxygen consumption rates is that increased clearance ofthe T3from the serum could
 
prevent a supraphysiological dosefrom occurring. However,it is likely that the 500
 
■ ■ ■ ■ /:-:\V-y:32^'A:v' /X 
ng/gBW dose ofT3 is so high that the animals are not able to compensate(or
 
compensateto a much lesser degree)and an increase in oxygen consumption is observed.
 
The 500 ng/gBW dose ofT3 is a pharmacologic dose which pushesthe limits ofthe
 
physiological scope ofresponses.
 
The oxygen consumption rates for normal and diabetic mice werefound to be time
 
dependent in that the rateswere different on day6than they were on day 10. On day6 no
 
change was observed in total and specific oxygen consumption rates ofnormal and
 
(iiabetic animals at the200 ng T3/gBW dose. Howeyef,on day lOamincfeasein both ^
 
total and specific oxygen consumptionfateswas observed in both normal md diabetic
 
nuce at the same dose ofT3. This suggests that the young animals were no longer capable
 
ofcompensating at the end stages ofthe experiment or that the metabolic response to Tj
 
required the full ten days ofT3 exposure to develop.
 
The increases seen in metabolic rates with T3treatment may be due to a variety of
 
physiological responses including increases in thermogenesis and/or a change in the fuel
 
source. Diabetic mice have been reported to have defects in thermogenesis which lead to
 
increased metabolic efficiency(32). Thermogenesis is directly increased by thjToid
 
hormones and indirectly through thyroid hormone potentiation ofthe thermogenic effects
 
ofepinephrine(33). Thus,the hyperthyroidism induced by the addition ofexogenous T3
 
to both the normal and diabetic mice may have lead to increased thermogenesis and thus,
 
increased metabolic rates. Although the body temperatures ofthe mice were not
 
measured,as the experiment progressed the mice receiving T3 felt warmer to the touch
 
compared to the vehicle treated control animals which supports the idea that these mice
 
were subjected to increased thermogenesis
 
While the total metabolic respoiise to Tjlikely accounts changes in oxygen
 
consumption,oxygen consumption rates are also influenced by the fuel source used bythe
 
mice. Garbohydrates usually provide the majbtsource offuel for energy metabolism(21).
 
However,as energy demands increase,the need for anotherfuel source becomes critical
 
and lipids play a major role as an alternative source offuel. Lipid catabolism, however,
 
requires more oxygen per gram offat than carbohydrate catabolism and therefore^ could
 
accountfor the ihcreased oxygenconsumption rates seen with T3treatment. A change to
 
lipids as the fuel source could only occur ifthe concentrations ofexogenous T3given in
 
this experiment could overcome the proposed suppressioh ofpituitary GH production and
 
release caused bythe hyperinsulinemia in diabetic mice(16). Subsequent production of
 
GH would then enable the T3-induced lipolytic response ofadipocytes to occur.
 
To evaluate a potential shift in fuel source serum lipid profiles were evaluated.
 
Nonfasting triglyceride levels Were studied previously byTuman and Doisy in diabetic
 
mice and their lean littermates(7). The triglyceride concentrations ofthe diabetic mice
 
were elevated at five weeks ofage when compared to the normal mice, 120+6 vs.84+4
 
mg/dl respectively. The triglyceride levels ofthe diabetic mice increased with age
 
attaining a maximum level of400+91 mg/dl at 19 weeks ofage while the normal mice
 
had triglyceride levels that remained relatively constant throughout the experiment.
 
Elevated serum concentrations oftriglyceride were also observed in diabetic mice
 
compared to their normal counterparts by Nishina et al(34). Triglyceride levels were
 
found to be approximately four-fold greater in the diabetic mice than in the normal mice.
 
The triglyceride levels seen in the previous experiments correlate with the levels seenin
 
the present study. It then became a question ofwhether lipid metabolism changed with T,
 
treatment and ifnormal and diabetic animals responded in similar magnitudes to T3.
 
The effect ofthyroid hormone on the serum concentrations oftriglyceride have been
 
studied in the past and have beenfound to be quite variable(35). A majority of
 
experiments indicate that hypothyroidism leads to increased levels oftriglyceride while
 
hyperthyroidism leads to decreased levels. Studies have suggested that the rate ofhepatic
 
synthesis and/or secretion oftriglycerides is decreased in hyperthyroidism and increased in
 
hypothyroidism. While this study attempted to evaluate serum lipid profiles the
 
experimental design did not allow forthe assessment ofspecific changes in triglyceride
 
synthesis, secretion, and disposal. The normal animals in the present study had serum
 
triglyceride levels that remained relatively constant at all doses ofT3indicating no net
 
change in circulating T3 concentrations. The control diabetic animals, which exhibit
 
hypertriglyceridemia, had elevated levels oftriglycerides which may be the result of
 
increased release oftriglyceridesfrom the livers(8)related to their effective "hypothyroid
 
status" due to T,resistance. The increased level ofserum triglycerides may also be due
 
the diabetic animals decreased ability to clear triglycerides from the bipod(8). The
 
addition ofexogenous T,to diabetic animals lead to a decrease in serum triglycerides and
 
this may be due to T3 suppression of triglyceride release from the liver leading to
 
increased storage and/or an increased rate ofremovalfrom the blood by metabolically
 
active tissues such as muscle. Ifthe metabolic demand for triglycerides exceeds the
 
synthesis and secretion by hepatocytes,the triglycerides will decrease in concentration in
 
the seram. These results suggest that T,influences serum triglyceride concentrations
 
however^ it is not possible to state whether it is synthetic or secretory control or uptake by
 
metabolically active tissues.
 
Although the intent wasto study all ofthe serum lipoproteins to evaluate lipid
 
transport,this was not possible because the VLDLand LDL bandson the agarose gel
 
were stained too lightly to quantitate. It was,however,pdssibleto evaluateHDL and
 
diabetic mice exhibited serum HDLconcentratipns that were six-fold greater than those
 
observed in normal mice. Previous studies have also shown that C57BL/KsJ diabetic mice
 
and genetically obesemice have elevated serum concentrations ofHDL(34,36). It is
 
interesting to note that the mice in both studies were subjected to an overnight fast prior
 
to blobd collection. The effect,ifany,this had on the serum HDL concentrations is
 
unknown. A direct comparison between the previous studies and this study cannot be
 
made since the absolute concentrations ofHDL were not determined.
 
The effects ofaltered thyroid status on plasma lipoproteins has been reviewed by
 
Heimberg,Olubadewo,and Wilcox(35). The results are inconclusive as to the effect of
 
thyroid hormone on serum HDL Concentrations. It has been reported that hypothyroidism
 
leads to elevated HDL cholesterol levels, however,other studies have shown HDL
 
cholesterol levels to be decreased. Hyperthyroidism has been reported to lead to
 
decreased serum HDL cholesterol levels. The resultsfrom the present study indicate that
 
thyroid hormone resistance, which is functionallyequivalentto hypothyroidism^ leadsto
 
increased serum HDL concentrations. Hyperthyroidism resulting from administration of
 
exogenous Tj,on the other hand,leads to decreased levels ofHDLin both diabetic and
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normal mice. It is clear that serum HDL concentrations are altered by Tj-sensitive
 
responses,but the nature ofthese processes remain undefined.
 
Although metabolism ofHDL has been the subject ofmany studies,the degradative
 
processes and the tissues involved in HDL disposal remain unclear(37). The results from
 
this study suggest that T3is an inhibitor ofthe release ofHDLfrom the liver or an
 
activator pfthe clearance ofHDLfrom the serum. Normal aninials given
 
Supraphysiologieal levels ofT3 exhibith decreasdinthe serurhdtoL c
 
16)which would be consistent with inhibitipn ofthe felpase bfHDL or an iricrease in the
 
disposal rate. That normal animals do not exhibit any htrther decrease in serurn Hp
 
concentrations at the highest doses ofTa niay indicate that maximal inhibitipn occur
 
the 100 ng Ts/jg BW dose. Ifthe elevated levels ofserum HDL seen in the diabetic
 
animals are due to a tissue insensitivity to the inhibitory effect ofT3 on the release of
 
HDLsfrom the liver, T3 resistance could lead to constitutive secretion ofHDLfrom the
 
liver thus leading to elevated serum HDL concentrations.
 
Since the half-life ofHDLis 5 to6 days(21)a two-fold increase in storage ofHDLs
 
should become apparent around day 5 ofthe experiment. IfHDL secretion stopped,in 5­
6 days the concentration ofserum HDL would decrease to 50%,assuming there was no
 
change in the rate ofdisposal. A50% decrease in serum HDL would also be expected if
 
the rate ofsecretion did not change but,the rate ofdisposal increased two-fold. During
 
the ten days ofobservation there was enough time to see another 50% reduction in the
 
serum HDL concentrations meaning that theHDLlevels could theoretically decrease a
 
total of75%. The senim HDL concentrations ofthe diabetic mice In the present study
 
decreased by60.49% at the 200 ng Tj/gBW dose which is less than what would be
 
predicted from above. Unfortunately,HDL values in the fully stimulated(500 ng Tj/g
 
BW)animals were not dbtained. Thus,T3 appearsto play a role in either inhibiting
 
hepaticHDL Secretion or increas;ing degradation pfserum HDL.
 
Interestingly,serum HDL concentrations in humans with NIDDM are stated to be
 
significantly lower than serum HDLlevels in normalindividuals(38). However,it is
 
imperative to note some critical differences between this study and those cited in the
 
literature. First, studies ofserum HDLlevels have previously been studied in humans(38)
 
while mice were used in this study. Although both are mammals and have many shared
 
characteristics ofNIDDM,it is possible that the difference in HDL profiles is due to a
 
difference in the nature ofthe defect. In contrast, it has been noted that humans with
 
NIDDM sufferfrom atherosclerotic vascular disease(38)while C57BL/KsJ db/db mice
 
have decreased susceptibility to atherosclerosis(34). SinceHDLis thought to play a role
 
in reducing vascular disease via cholesterol scavenging(38)it may be that humans with
 
NIDDM are more susceptible to atherosclerotic vascular disease than mice because ofthe
 
decreased levels ofserum HDLfound in human subjects. Previous studies found an
 
inverse correlation between HDLlevels and the susceptibility to atherosclerosis in diabetic
 
mice,the higher the serum HDLconcentration the lower the risk ofatherosclerosis
 
(34,36). Third,the subjects discussed in the literature had been subjected to an overnight
 
fast prior to blood collection(39)while the mice in the present study were not subjected
 
to fasting. The importance ofthis difference seemsto be negligible since previous studies
 
with diabetic mice involved an overnight fast prior to blood collection(34,36) and these
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animals dlso had blevated serum concentrations ofHDL. Thus,the serum concentrations
 
ofHDLin subjects with NIDDM appear to be dependent Upon the particularform of
 
ISTtDDM,hunians have decreased while mice have inereased levels ofHDL,
 
Further studies will need to be Conducted tO ascertain the fuel source used by diabetic
 
miceto sustain the elevated metabolism under T3 stimulation. One way to ascertain the
 
fuel source used would require a repetition ofthe treatment protocol used in this
 
experiment with simultaneous measurement ofboth oxygen and carbon dioxide
 
consumption rates. These would then be used to calculate the respiratory quotient(RQ)
 
to determine ifcarbohydrates, proteins, or fats were being metabolized to provide the
 
energyfor the increased metabolism. Another important question which may be addressed
 
is whether the increased levels ofserum HDL seen in the diabetic mouse are due to T,
 
resistance. One way to study the effects OfTjon the release ofHDLfrom the liver may
 
be to inhibit the conversion ofT4to T3 by blocking the 5'-monodeiodinase with iopanoic
 
acid(40). This would lead to a h5q)oth3Toid state and,ifthe normal action ofT,is
 
inhibition ofproduction/release ofHDLfrom the liver, would lead to increased serum
 
HDL concentrations. This would be the first study that examines the influence ofT3on
 
HDL production.
 
Previous studies examining the effects ofT3treatment on body fat content in obese
 
micefound that the body fat content decreased with increasing doses ofT3(41). Inthe
 
present study the percent body fat ofnormal mice remained relatively constant at all doses
 
ofT3 except at 100 ng Tj/gBW where a small but significant increase was seen. The
 
diabetic mice,on the other hand,exhibited decreases in percent body fat that were nearly
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linearly dependent on the dose ofTj. The differences in responses between normal and
 
diabetic mice may be due to diabetic mice being T3 resistant. The thyroid hormone
 
resistance may allow excessive fat deposition and the addition ofthe exogenous T3 may
 
enable diabetic mice to overcome this resistance. Thus,the normal balance ofstorage and
 
release offats in adipocytes may be restored.
 
This study has shown that diabetic mice are T3 resistant and the degree ofT3 resistance
 
in mice with NIDDM is age-dependent. The differences in specific oxygen consumption
 
rates between normal and diabetic mice were shown not to be due to a metabolic scaling
 
phenomenon related to body mass,but rather a Tj-responsive physiological mechanism,
 
likely found in the lean body mass or inactive adipose tissues. The elevated levels of
 
serum HDL in untreated diabetic mice and subsequent reductions with T3 treatment also
 
suggest that T3 suppresses hepaticHDL production and/or release and that this process is
 
similarly resistant to the action ofT3 in the C57BL/KsJ db/db diabetic mouse. This is the
 
first report ofT3 regulation ofHDL and extends the observations ofT3resistance in the
 
C57BL/KsJ diabetic mouse to include alterations in T3regulated lipid metabolism.
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Appendix III. Total oxygen cdnsurnption rates presented as mean±SEM.
 
NORMAL	 DIABETIC
 
Ong 100 ng 200tig: 500 ng Ong ;100 ng 200 ng 500ng 
; Ts/g 
-MS. m' ""Ts/g " 
BW BW BW BW BW BW BW BW 
Day 1.1Q9 1.075 ^ i:022 :L086 1.117 1.324 1288 1.394 
■:,' ■ : ;±';
.::''V± ;;v.	 : ±-; 
0.050 0.077 0:066'; 0;022; 0.151 0.177 0.108 0.092 
pay 1 187 1.232 i1:193 1.254 1.621 1.546 1.481 1.557 
2:; ■ " + ; i ': .: '; + ■■ ■ I' /d:' ' ■;■ ±: + 
0.040 0>047 0.059 0:073 : 0.036 0.065 0.037 0.045 
Day 1.355 1.319 1.296 1.294 1691 1.562 1.537 1602 
■± :	 : :: d . + ■■■ d-­
0.060 0.012 : 0;048 0.062 0:030 osm 0.091 0:062 
Day 1.462 1.439 1.602 1.652 1.669 1.660 1.728■ 1^523- ' 
+:± : • ■ ' ±': . . ^ ± 
.0^078; 0.053 ;0.036 0.124 0.085 0.090 0.04O 0.024 
Day 1.526 1.350 1.504 1.655 1789 1764 1.702 4.924 
+■; . ■ ;d:'" 
0.052 0.033 0.097: 0d78 0.020 0.083 0.072 0.086 
1;607\ ■?il.593d; 1.576 1.786 1.837 1898 1.809 2.050; 
Day ..±: . ■ ;" dl. ■ ' ■± : ; :•■+■ ' ■ ■ ..■; 
A,: ': 0.080^ 0.051 0:067 0:051 0.048 0.060 0.081 0:035 
Pay 1.330 1.243 i-336 1:506 1.615 1.686 1761 1:949 
■ '2 + ±	 ■ ' ^ ■±':'' ■;d-' ' ' \± 
0.049 0.030 0.094 0.076 o;o6i 0.073' :: 0,093 O063 
Day 1.249 1.453 1.397 : 1.604: ■1.618 1711 ' 1:834; ■li912 
+ + l/A,:/:. ' ' ■" ±' :'" 
0.109 0.030 0.027: G.062 0.046 0.037 o:o49 0:144 
Day 1.243 1.414 ■ i-285 1.470 1.546 :1-655 1702 1:980; 
i::d'd ■	 : ' ■ id' 
0.055 : 0.062 0.061 0.073 o:o59 0.042 0.062 0.041 
Day 1176 1:235: 1.288 1.400 :;i.422d 1789 1.708 1.968 
10.	 ■ ■ ■ d d ' . ' -d: ■: ■ 
0;061 : 0.025 0:015 0.050 0.050 0:122 :0-068 0,097 
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Appendix IV. Specific oxygen consumption rates presented as mean+SEM.
 
■ ^:NORMAL .DIABETIC.' ' 
0tig 100 ng 200 ng 500 ng 0ng 100 ng 200 ng 500 ng 
Ts/g Tj/g 5T3/g ;: Tj/g : T3/g 7M:' ; Tj/g 
BW BW BW :BW BW BW BW BW,:. 
Day 0:052 0.049 0.047 0.049 0.024 0.029 0.028 0.030 
:: i ± X ' ■ X ■: 
Oi0038 0.0036 0.0040 0.0014 0.0032 0.0029 0.0024 0.0018 
Day 0.O55 0.056 0.054 0.055 0.035 0.034 0.032 0.033 
: - ' ■ ±. : ■ 
0;0023 0.0028: 0.0037 0.0019 0.0010 0.0009 0.0008 0.0012 
Day 0.064 0.060 
' ■ ' 'xX 
0.060 
; ±' 
0.058 
;'■■■ ■+■ 
:0;037 
■ ■ ' ±­ ,'' ■ ■ 
0.035 0.033 
' :±\: 
0.035 
0.0034 : 0.0016 0.0035 0.0012 0.0009 0.0014 0.0017 0.0022 
Day O.069 0.071 0.067 0.073 0.035 0.037 0.036 0.038 
'.X4' ' ± ± ■ + , + 
o:0044) 0.0025 0.0031 0.0037 0.0017 0.0011 0.0012 0.0014 
Day 0:073:;; 0.064 0.070 
":X 
0.076 
'X^:±:: ■ 
0.038 
:■ ± ■ 
0.040 0.038 0.043 
;6.oo37: 0.0020 0.0058 0.0032 0.0006 0.0018 0.0009 0.0007 
Day 0.075 ; 0.074 0.073 o;o82 0.039 0.044 0.041 0.047 
:v .6X'­
0.0050: 0.0027 0.0038 0.0031 0.0009 0.0026 0.0009 0.0013 
Day 0;063;:E 0.057 0.062:: 0.069 0.034 0.039 0.040 0.046 
0.0037 ± ■ 
0.0011 0.0046 0.0037 0.0012 0.0024 0.0013 0.0032 
Day 0.059 0.066 0.065 0.073 0.034 0.040 0.043 0.046 
+ + + + • + + 
0.6044 0.0015 0.0016 0.0041 O.OOM 0.0018 0.0012 0.0031 
Day 0.058 0.064 0.059 0.065 0.033 0.040 0.040 0.048 
9 + + + + + ' + + + 
0.0025 0.0029 0.0030 0.0033 0.0011 0.0012 0.0015 0.0009 
Day 0.055 0.055 0.059 0.062 0.030 0.044 0.041 0.050 
10 + + + + ■ ■ ±: :-±'' 
0.0038 0.0012 0.0011 0.0018 0.0009 0.0038 0.0009 0.0026 
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Appendix V.
 
(mg/dL)'
 
100 200
 500
 
;.,-ng;T3/g;BWS:^ ngT3/gBW ngT3/gBW ngT3/gBW
 
NORMAL 79.55+ 3:37 76:85±4;13 107.78+6.61 86.93±6.20
 
DIABETIC : 365.06+20-60 225.43+:i7;50 :25R73±33.28- .2iI7.05+ 13:50;
 
Appendix VI. Serum HDL concentrations presented as mean+SEM.
 
(O-D)
 
: 100.^ ; v: ^ 200
 
: ng Tj/gBW ■ - ^ ngiygBW/ ngT3/gBW 
NORMAL 0.386+0.116 ; ■ 0.144+0.034 ; 0.220±0.081 
DMETIC 1.544+0.053 ; 1:134+0.062 ; 0.610±0.056 
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